ClinicalTrials.gg
CompletedNCT06152276SH-SOC23Updated May 4, 2026

SafeHeal Diverting Ileostomy Pivotal Study

An observational study in Colorectal Cancer and Stoma Ileostomy, sponsored by SafeHeal Inc. Completed at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by SafeHeal Inc · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
132
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
199th of 325
132 · median 220
Started
2024
with 123 others
Observational
326 of 2,342
68 open now
Registered
1,949th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 199th largest by enrollment of the 325 observational ones that give a count, is one of 124 that started in 2024, is one of 326 observational ones, and was the 1,949th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This SafeHeal study is designed to assess the overall safety of the low anterior resection (LAR) standard of care cancer treatment by establishing a definition of major complications. The current literature on standard of care reports adverse events/complications but does not provide a single endpoint that can be used to compare the safety of LAR cancer treatment to alternative therapies or treatments. This study will allow for the establishment of a new single safety endpoint for LAR standard of care cancer treatment.

Read the detailed description

This SafeHeal study is designed to assess the overall safety of the low anterior resection (LAR) standard of care cancer treatment by establishing a definition of major complications. The current literature on standard of care reports adverse events/complications but does not provide a single endpoint that can be used to compare the safety of LAR cancer treatment to alternative therapies or treatments. This study will allow for the establishment of a new single safety endpoint for LAR standard of care cancer treatment.

The data from this study could serve as the historical control arm data of a SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-3) Pivotal Study designed as a prospective, non-randomized, sequential, controlled, multicenter trial comparing the investigational device, the next generation Colovac Anastomosis Protection Device, to the standard of care (SOC), diverting ostomy.

03

Conditions studied

  • Colorectal Cancer
  • Stoma Ileostomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with colorectal cancer undergoing low anterior resection following by a diverting loop ileostomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (18 years of age or older)
  2. Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for , based on multidisciplinary team recommendations.
  3. (ECOG) Performance Status ≤ 2
  4. Willingness to comply with protocol-specific treatment and study visits and to sign a written Form

Exclusion criteria

Exclusion Criteria:

Preoperative

  1. History of left colitis
  2. Known allergy to nickel or other components of the Colovac System (not applicable for control cohort)
  3. Pregnant or nursing female subject
  4. Concomitant major surgical procedure in combination with Colorectal resection (i.e., hepatectomy)
  5. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo protocol described procedures or interfere with the interpretation of study results including, but not limited to:

    1. Stage IV colorectal cancer unless curative intent R0 resection is planned AND there is no associated peritoneal disease
    2. Immunodeficiency ( \< 500 CU MM)
    3. Systemic therapy within the past 6 months
    4. Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery
    5. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study
    6. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, or carcinomatosis
    7. Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging
    8. Severe malnutrition defined as 10% weight loss within 3 months prior to enrollment.
  6. The subject is currently participating in another drug or device study

    Intraoperatively:

  7. Occurrence of any of the following during the colorectal surgery:

    1. Blood loss (>750 cc)
    2. Blood transfusion
    3. Any new sign of bowel ischemia
    4. Positive air leak test
    5. Inadequate bowel preparation
    6. Anastomosis location greater than 10 cm from the anal verge
    7. Any other surgical complications or intra-operative risks that may place the patient at greater risk from study procedures
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
132 participants (actual)
Patient registry
No

Groups and cohorts

  • Standard of Care Arm

    Diverting loop ileostomy following low anterior resection of colorectal cancer

    Other: Diverting loop ileostomy

Interventions

  • OtherDiverting loop ileostomy

    Diverting loop ileostomy following low anterior resection of colorectal cancer

06

What researchers measure

Primary outcomes

  1. Early anastomotic complications

    Early anastomotic complications

    Time frame: 9 months

  2. Overall major complications

    Major complications

    Time frame: 9 months

07

Study locations

22 sites
  • Kaiser Permanente - Los Angeles
    Los Angeles, California 90027, United States
  • Keck Medicine of USC
    Los Angeles, California 90033, United States
  • USC Keck Hospital
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of Miami
    Miami, Florida 33146, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01605, United States
  • Maimonides Medical Center
    Brooklyn, New York 11219, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • New York Presbyterian Cornell
    New York, New York 10065, United States
  • Lenox Hill Hospital
    New York, New York 10075, United States
  • Novant Health
    Winston-Salem, North Carolina 27103, United States
  • Lankenau Medical Center
    Wynnewood, Pennsylvania 19096, United States
  • UZA
    Edegem, Antwerp 2650, Belgium
  • UZ Leuven
    Leuven, Flemish Brabant 3000, Belgium
  • Bordeaux Colorectal Institute
    Bourdeaux, New Aquitaine 33000, France
  • Chu du Rouen
    Rouen, Normandy 76031, France
  • Hopital Saint-Louis
    Paris, 75010, France
  • Hôpital Saint Antoine Paris
    Paris, 75012, France
  • Humanitas Research Hospital
    Rozzano, Lombardi 20089, Italy
08

References and documents

Publications

  • Pastier C, Sylla P, Lee SW, Spinelli A, Komen N, Marks J, Martz J, Rhee R, Maykel J, Marcet J, Denost Q, Zaghiyan K, Davids JS, Paluvoi N, Hiller D, McLemore EC, Maggiori L, D'hoore A, Jafari MD, Poylin V, Buzas CJ, Tuech JJ, Lefevre JH. Safety and effectiveness of the Colovac anastomosis protection device compared with diverting ileostomy after low anterior resection: protocol for an international, multicentre, prospective, non-randomised comparative study (SAFE-3). BMJ Open Gastroenterol. 2026 Jun 12;13(1):e002235. doi: 10.1136/bmjgast-2025-002235. PubMed 42285586 ↗

Individual participant data

Plan to share: No — The data is confidential and only available upon a reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jan 2026, 24 months.

Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 24 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 30, 2023
StartActual
Jan 1, 2024
Primary completionActual
Jan 30, 2026
CompletionActual
Jan 30, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06152276
Lead sponsor
SafeHeal Inc
Responsible party
Sponsor
First posted
Nov 30, 2023
Start date
Jan 1, 2024
Primary completion
Jan 30, 2026
Completion
Jan 30, 2026
Last update
May 4, 2026

Study contacts

Patricia Sylla, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion